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Brief description of the novelty and impact of the article:  
For the first time, we explored DNA methylation signatures in adjacent cervical intraepithelial 
neoplasia from the same cervices. Our study indicates that distinct histopathological grades 
of CIN have characteristic epigenetic patterns. A clearer understanding of molecular changes 
leading to CIN3 could provide more accurate biomarkers to improve diagnosis and therapy, 
facilitating a reduction in healthcare costs and unnecessary treatments in HPV-positive 
women. 
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Abstract 
The evolution of precancerous cervical lesions is poorly understood. A widely held model of 
cervical intraepithelial neoplasia grade 3 (CIN3) development is sequential progression from 
normal through CIN1 and CIN2 to CIN3. Another hypothesis, the “molecular switch” model, 
postulates that CIN3 can evolve directly from human papillomavirus (HPV)-infected normal 
epithelium without progressing through CIN1 and CIN2. To shed light on this process, we 
compared DNA methylation of selected human biomarkers and HPV types in two groups of 
CIN1: CIN1 that were near or adjacent to CIN3 (adjacent-CIN1) and CIN1 that were the 
principal lesions with no CIN3 detected (principal-CIN1). 354 CIN (CIN1 and CIN3) and normal 
tissue areas were dissected and typed for HPV from 127 women who underwent loop 
electrosurgical excision procedures (LEEP). Methylation of genes EPB41L3 and the viral 
regions of HPV16-L1/L2, HPV18-L2, HPV31-L1 and HPV33-L2 were determined by a highly 
accurate quantitative pyrosequencing of bisulfite converted DNA. There was a significant trend 
of increased methylation with disease grade comparing normal to CIN1 and CIN3 (p<0.0001). 
Adjacent-CIN1 predominantly shared the same HPV types as the CIN3, however, methylation 
differed substantially between adjacent-CIN1 and CIN3 (p=0.008).  In contrast diagnostically 
principal-CIN1 had an indistinguishable methylation distribution compared to adjacent-CIN1 
(EPB41L3: p=0.49; HPVme-All: p=0.11). Our results suggest that progression from normal 
epithelium to CIN1 or CIN3 is usually promoted by the same HPV type but occurs via distinct 
DNA epigenotypes, thus favouring the “molecular switch” model. 
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Abbreviations: Adj.: adjacent; AVER: average; CIN: cervical intraepithelial neoplasia; CpG: 
5'-Cytosine-phosphate-Guanine-3'; CTT χ2: Cuzick Test for Trend statistic; DNA: 
deoxyribonucleic acid; hr: high-risk; E2BS: E2 binding site; EDTA: Ethylenediaminetetraacetic 
acid; FFPE: formalin-fixed paraffin-embedded; HCl: hydrochloric acid; HPV: human 
papillomavirus; HPV16: human papillomavirus type 16; HPV18: human papillomavirus type 
18; HPV31: human papillomavirus type 31; HPV33: human papillomavirus type 33; HPVme: 
HPV methylation; IMP: data imputation; KWT χ2: Kruskal-Wallis Test statistic, LEEP: loop 
electrosurgical excision procedure; µL; microliter; n: number of samples; ng: nanogram; Norm: 
normal; qPCR: quantitative polymerase chain reaction; Prin: principal; SDS: sodium dodecyl 
sulphate; TSS: transcription start site; URR: upstream regulatory region; vs: versus. 
 
Introduction 
Human papillomavirus (HPV) infections account for an estimated 530,000 new cervical 
cancers and 270,000 deaths annually, most of which occur in developing countries [1-3]. More 
than 25 types of HPV are transmitted through sexual contact but most infections do not cause 
symptoms and are cleared after a short time. When an infection is persistent with one or more 
high-risk HPV (hrHPV) there is an increased chance of cervical intraepithelial neoplasia (CIN2 
or CIN3) [4-8]. It was originally thought that cervical cancer evolved from HPV infected normal 
cervical epithelium via a “sequential progression” model (Figure 1). In this model, a long-
lasting HPV infection would cause cervical intraepithelial changes in a consecutive way, from 
HPV infected normal tissue to CIN1, CIN2, CIN3 and finally cancer [9]. However, an alternative 
idea is that CIN1 may not be necessary for the development of CIN3 [10, 11] and that CIN3 
could evolve directly from normal epithelium infected by HPV following a “molecular switch” 
model (Figure 1). This means clinically relevant CIN3 may develop fairly rapidly following HPV 
infection [12]. As a consequence, CIN1 lesions in general and most CIN2 may not be precursor 
stages of cervical cancer, but rather the visible effects of a productive HPV infection. It may 
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then take 10–12 years to develop invasive cervical cancer from CIN3 [13, 14]. A clearer 
understanding of molecular changes leading to CIN3 could provide more accurate biomarkers 
to improve diagnosis and therapy. 
Looking at the methylation level of certain genes is a way to shed light on the molecular 
progression of precancerous cervical lesions. DNA methylation is a reproducible physical 
epigenetic change involved in a variety of cellular processes that plays an important role in 
cancer progression [15]. Numerous studies have highlighted the importance of host and viral 
gene methylation in the development of cervical cancer and potential use as biomarkers to 
triage HPV positive patients [16-24]. A strong association has been observed between DNA 
methylation patterns and CIN of various grades in both cervical scrapes and biopsies. 
Typically, higher methylation is observed in patients with advanced intraepithelial lesions and 
carcinoma.  
In this study we investigated whether methylation data could bring evidence in support of either 
the molecular switch or the sequential progression model or both. We used epigenetic markers 
and HPV typing to investigate the two main models of precancerous cervical disease 
progression in areas of cervical lesions with discrete coexisting foci of different grades. We 
sought to determine whether levels of DNA methylation were a characteristic of lesion grade. 
Our primary aims were to contrast methylation in CIN1 in two possible configurations:  a) 
adjacent-CIN1 vs CIN3 from the same women and b) adjacent-CIN1 vs principal-CIN1 lesion 
from different women. We hypothesised that if methylation levels were different between 
adjacent-CIN1 and CIN3 on the same cervix but similar between adjeacent-CIN1 and 
principal-CIN1, this would add support to the “molecular switch” model. On the other hand, if 
the methylation levels overlapped substantially between grades and adjacent-CIN1 showed 
higher methylation levels than principal-CIN1 then; “the sequential progression” model would 
be favoured. A secondary aim was to determine whether adjacent lesions were usually 
infected by the same or different HPV types. The study was made possible by our collection 
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of carefully annotated Loop Electrosurgical Excision Procedure (LEEP) cervical tissues 
(Figure 2).  
 
Material and methods 
Our goal was to compare HPV types and DNA methylation patterns in different kinds of 
cervical lesions that we obtained from the LEEP surgical tissues. Tissue areas to dissect 
were identified by microscope-based pathology review and annotation.  
 
Study population and clinical specimens 
Archived material from the Predictors studies (Ethics no. 05/Q0406/57) collected from 2005 
to 2009 was used [25, 26]. All patients with moderate and higher dyskaryosis in the baseline 
liquid-based cytology (ThinPrep; Hologic, Bedford, USA) and those with persistent mild 
abnormalities were sent for colposcopy. Before colposcopic examination an exfoliated cell 
specimen was taken from the cervix into PreservCyt (Hologic Inc.) for HPV typing. Additionally, 
punch biopsies were taken from areas with abnormal appearance to determine the histological 
diagnosis of the patients. Final histopathological diagnoses were based on reviews by at least 
two pathologists. The highest grade of abnormality seen in the biopsy was used. If the 
pathologist panel review confirmed CIN2+, patients underwent treatment by LEEP and the 
surgical tissues were fixed in formalin and embedded in paraffin (FFPE). We used FFPE 
punch biopsies from 104 women and FFPE LEEP tissues from 127 women (Figure 2). We 
excluded women who had a final diagnosis of CIN2 from the study to minimize confusion from 
inaccurate pathology diagnoses; this was because of strong evidence that CIN2 in particular 
is a less reliable diagnosis than CIN1 or CIN3 and may not be a distinct biological entity [27-
31]. 
 
Lesion dissection, annotation and DNA extraction 
For the biopsies, twelve 5μm FFPE sections of normal, CIN1 and CIN3 were cut on a 
microtome using a new blade for each block. Sections were stored at -70°C until DNA 
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extraction. Entire sections were scraped from the slides using a scalpel and deparaffinised 
using three washes in xylene and one wash with 100% ethanol. DNA was extracted using 
QIAamp DNA FFPE Tissue Kit (QIAGEN) according to manufacturer’s instructions with an 
initial incubation step at 56°C for 16-18 hours with proteinase K. The DNA concentration was 
measured using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific).  
 
For the LEEP blocks, sections were cut using a sandwich cutting procedure as described in 
by [32] using a new blade for each block (Supplementary Figure 1) [32]. Negative controls 
(breast tissue) were used after every 10 blocks to rule out contamination. The negative 
controls all tested negative for HPV. Twelve 5um FFPE sections of the 127 LEEP specimens 
were cut. The first and last sections were H&E stained and the remaining ten sections were 
used for DNA extraction. The H&E slides were carefully marked by an expert histopathologist 
(J Carton) to indicate different areas of CIN and normal tissues and used as guides for 
subsequent precise scalpel-based dissection of the corresponding unstained sections under 
low power magnification. Sections were separated into two categories (CIN1 and CIN3 cases) 
depending on the highest-grade lesion found. Where possible, normal squamous epithelium 
adjacent to CIN1 were also dissected. The CIN3 cases also included additional tissue (where 
possible) extracted from adjacent normal and CIN1 areas. Only one (if any) adjacent normal 
area was dissected per CIN1 or CIN3 case. However, if sections contained multifocal CIN1 or 
CIN3 lesions, additional areas were dissected and processed separately. Scraped areas were 
separated into different tubes for DNA extraction. Because of the small amount of starting 
material, dissected areas were deparaffinised using 160µL of hexadecane followed by a 5-
minute incubation at 56°C. Two hundred microliters of universal extraction buffer containing 
50mM Tris-HCl pH 8.0, 1mM EDTA and 0.05% SDS was added to tissues along with 400mg 
of Proteinase K (QIAGEN) and incubated overnight at 56°C followed by a one-hour incubation 
at 90°C. The lower phase was then transferred to a new tube and stored at -20°C before PCR.  
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HPV type detection 
The 354 dissected areas from LEEP samples were tested using the PapType High Risk HPV 
Detection and Genotyping kit (PapType kit, Genera Biosystems Ltd) according to the 
manufacturer’s instructions (Figure 2). The kit is able to detect 13 hrHPV types (HPV16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), one possibly hrHPV type (HPV66) and two low-
risk types (HPV6 and 11). The PapType test was performed with 10µL of DNA in a final 
reaction volume of 20µL with the addition of 0.4µL of Tween 20 (2%). The PCR reaction 
amplifies a variable region of the L1 gene. A fragment of the human cardiac myosin light chain 
gene (MLC-1) was co-amplified in the same reaction vessel as a quality and quantity control. 
The results of HPV typing from the LEEP samples were compared to each other and their 
corresponding cervical scrape samples taken before colposcopy (Figure 2). The exfoliated 
cells were genotyped by Linear Array (Roche Diagnostics, Rotkreuz, Switzerland) for 
Predictors 1 and by BD HPV test (BD Diagnostics, Franklin Lakes, USA) for Predictors 2 [25, 
33].  
 
DNA methylation assays 
DNA methylation was measured by a highly accurate pyrosequencing assay as previously 
described [34]. Sodium bisulfite conversion of the genomic DNA was done using 200ng DNA 
obtained from the punch biopsies and 20L of the DNA extract from the LEEP sections using 
the EZ DNA Methylation Kit (Zymo Research, CA, USA) following the manufacturer’s 
instructions.   
The punch biopsies were used to determine the most informative genes for the main model 
development study using the LEEP sections (Figure 2). Analysed human regions on the 
biopsies were based on our and others’ previous work and included EPB41L3 (CpG sites 425, 
427 and 438 relative to transcription start site (TSS)) and MAL (CpG sites 529, 533, 535, 539, 
and 542 relative to TSS) [24, 35]. Viral regions included the HPV16-URR (CpG sites 31, 37, 
43, 52, 58, 7428, 7434, 7455 and 7461, which comprises E2BS1, 3 and 4), HPV16-L1 (CpG 
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sites 6367 and 6389), HPV16-L2 (CpG sites 4238, 4247, 4259 4268, 4275) and HPV18-L2 
(CpG sites 4256, 4261, 42656, 4269, 4275, 4282)[21, 22]. None of the samples were excluded 
on the basis of their HPV type. Amplification of CpG positions were done using the PyroMark 
PCR kit (QIAGEN, Germany) with 10ng of converted DNA (except for HPV18-L2 PCR, for 
which 20ng of DNA was used) in a 25µL volume with final concentration of reagents of 1x for 
Coral Load and PyroMark mix, 0.2M of PCR primers. PCR cycling conditions were 15 
minutes at 94°C, followed by 45 cycles of 94°C, 54°C (51°C for HPV16-L2, 55°C for HPV16-
URR), 72°C each for 30 seconds and a final extension at 72°C for 10 minutes. PCR products 
were pyrosequenced using a PyroMark™Q96 ID (Qiagen) instrument as previously described 
[36]. Pyrosequencing runs included positive controls of known methylation level (0%, 50% and 
100%) to allow standardised direct comparisons between different primer sets and a negative 
control. For each gene and viral region, the methylation percentage was averaged over all the 
CpG positions investigated since we have previously shown that these CpGs are always 
similarly methylated within a particular sample [21, 22]. 
For the main study on the LEEP sections, based on the pilot results obtained from the punch 
biopsies, we decided to concentrate on human gene EPB41L3, the L1 and L2 regions of 
HPV16 and the L2 region of HPV18 (Figure 2). To the assays above, we also added newly 
developed assays for HPV31 and HPV33 [37, 38]. These were two CpG positions in the L1 
region of HPV31 (6352 and 6354) and four positions in the L2 region of HPV33 (5557, 5560, 
5566 and 5572). Assays were run as previously described [22]. We used 8µLof bisulfite 
converted DNA in the PCR using the PyroMark PCR kit as described above. Percentage 
methylation was averaged over all the CpG positions investigated and methylation levels were 
further averaged over all HPV types to create a single variable for HPV methylation called 
HPVme-All (Figure 2) because there were insufficient data for HPV18, HPV31 and HPV33 
separately. For women with multiple samples of the same type (for example, when two CIN1 
or three CIN3 areas were dissected), the percentage methylation was averaged to produce a 
single value per lesion type per woman (Figure 2). 
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Assays were performed blinded by the technicians with cases and controls randomly 
intermixed, thereby minimizing concerns of biasing batch effects. We used a pre-specified 
study design and the statistical analyses were done after molecular testing was finished and 
were independent of the team that produced the laboratory results. 
 
Statistical analysis 
Analyses were performed according to a pre-specified statistical analysis plan, which was 
blinded to the methylation data. For the pilot study using punch biopsies, Kruskal-Wallis rank 
sum tests were used to compare averaged percentage methylation data between normal, 
CIN1 and CIN3 cases.  
For the main study using LEEP samples, paired and unpaired Wilcoxon tests were performed 
as appropriate to compare DNA methylation levels between groups using EPB41L3 and 
HPVme-All as predictors. DNA methylation missing values of HPVme-All were imputed with 
the value of zero for any hrHPV negative sample and by a median regression with age as a 
predictor and DNA methylation as an outcome for hrHPV positive samples. Missing values for 
EPB41L3 were imputed by a median regression with age as a predictor and DNA methylation 
as an outcome independently of their HPV infection status (Figure 2).  
All p-values were two-sided with significance set at α < 0.05. No adjustments were made for 
multiple comparisons. Analyses were undertaken using R statistical software version 3.3.1.  
 
Results 
Pilot and main study: specimens and strategy 
A pilot study was performed on 104 punch biopsies to select a set of informative biomarkers 
for the main study. The methylation of candidate biomarkers EPB41L3, MAL, HPV16-L1, 
HPV16-L2, HPV16-E2 binding sites (1, 3, and 4), and HPV18-L2 is presented in 
supplementary Figure 2 and supplementary Table 1. MAL and the HPV16-E2 binding sites 
were dropped from further study due to inadequate effect size. Although the L2 region of 
HPV18 was not significant in the pilot study due to small sample size (Supplementary Figure 
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2), methylation of this region was assayed in the main study because of the importance of 
HPV18 as a carcinogenic HPV. To these assays we added biomarkers in the L1 region of 
HPV31 and the L2 region of HPV33, which were validated as informative in different studies 
[22, 37]. 
For the main study we used dissected LEEP tissues from 127 women (Figure 2). The women 
were subdivided into CIN1 and CIN3 cases depending on the highest grade intraepithelial 
lesion diagnosed in the available tissues. There were 49 women classed as principal-CIN1 
(where no CIN3 was present on the cervix) and 78 as CIN3 cases. A majority (n=53) of the 
CIN3 cases were classed as multifocal because they presented adjacent lesions of different 
grades (adjacent-CIN1 or adjacent-CIN3). The process gave us a total of 354 dissected CIN 
or normal areas (Figure 2).  
 
Nature of methylation patterns in multifocal CIN3   
A paired analysis on tissue isolated from the same cervices indicated that methylation of the 
normal tissue and CIN1 adjacent to CIN3 were significantly different from the CIN3 lesions. 
This was true for both EPB41L3 (normal vs CIN3: p<0.0001 and CIN1 vs CIN3: p=0.008) and 
HPVme-All (normal vs. CIN3: p<0.0001 and CIN1 vs. CIN3: p=0.0011; Figure 3). The normal 
tissue samples were also different from the CIN1 lesions (EPB41L3: p=0.005 and HPVme-All: 
p=0.0004). Another way to view the data is to test the differences in methylation levels 
between the paired histopathological groups on a per-cervix basis. In figure 4, we plotted 
percentage differences in methylation between all paired measurements for EPB41L3 and 
HPVme-All markers. A large majority of methylation differences were positive, suggesting an 
increase of methylation as diagnoses changed from CIN1 to CIN3 in each woman. 
 
Normal tissue and CIN1 lesions have characteristic methylation levels regardless of whether 
they are from unifocal or multifocal lesional cervices 
Methylation levels of normal tissues located near CIN1 or CIN3 were similar for both EPB41L3 
(p=0.21) and HPVme-All (p=0.16) (Figure 5). Of greater interest, the pattern was the same for 
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CIN1. Methylation levels of principal-CIN1 were not different from adjacent-CIN1 in CIN3 for 
EPB41L3 (p=0.49) nor HPVme-All (p=0.11) (Figure 5). In fact the median of EPB41L3 for 
adjacent-CIN1 appeared slightly (but non-significantly) lower than for primary-CIN1 and 
supports a model where EPB41L3 DNA methylation levels may exist as discrete haplotypes, 
characterizing and possibly controlling the morphological appearance of pre-cancerous 
lesions.  
 
Association of high-risk HPV positivity and severity of lesions  
354 dissected areas from LEEP samples were HPV typed (Figure 6). A majority of principal-
CIN1 (87%), adjacent-CIN1 (97%) and CIN3 (99%) were high-risk HPV positive. Most of the 
CIN1 and CIN3 were infected by a single hrHPV type (69% of principal-CIN1 and 81% 




Comparison of HPV types found in adjacent lesions and between LEEP samples and 
exfoliated cells  
In multifocal CIN3, a majority of adjacent-CIN1 were infected by the same hrHPV as the CIN3 
(87%, supplementary Figure 3). HPV type results were classed as compatible when some 
HPV types matched but one or the other paired sample also presented additional types. 
Normal tissues showed a somewhat lower similarity to their adjacent-CIN1 (41% with same or 
compatible types to adjacent-CIN1 and 45% compatible to principal-CIN1) and adjacent CIN3 
(51%). Furthermore, we noticed that when multiple lesions of the same grade were present in 
a multifocal CIN3, they were generally infected by the same HPV type (13/16=81% in CIN3 
and 11/12=91% in CIN1), which is compatible with a single infection event from which multiple 
lesions arose. However, in principal-CIN1 only 56% (9/16) of adjacent CIN1 were infected by 
the same HPV type, consistent with greater diversity of low-grade lesions, perhaps due to 
multiple infection events combined with both transient and short-term persistent HPV 
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infections.  
HPV types in macro-dissected LEEP samples were also compared to their corresponding 
exfoliated cells from cervical scrapes at colposcopy and a good agreement was found 
between the two (Supplementary table 2). The HPV types found in 99% (77 out of 78) of the 
CIN3 and 88% (43 out of 49) of CIN1 lesions matched or were compatible (i.e. additional types 
were found either in cervical scrapes or in the dissected areas from LEEP) with the 
corresponding exfoliated cell genotyping results.  
 
Discussion  
The main goal of our study was to characterize DNA methylation events associated with 
progression to CIN3. We show in our detailed methylation and HPV typing analyses that the 
topography of cervical HPV infection, the resultant intraepithelial neoplasia and the molecular 
patterns are heterogeneous and quite complex. We report here for the first time that, although 
adjacent CIN of different grades usually contain the same hrHPV type(s), methylation patterns 
are significantly different and characteristic of the lesion grade. 
Previously published evidence of genetic alterations that accumulate during cervical 
tumorigenesis indicate a common cellular origin for multifocal lesions, suggesting that different 
intraepithelial lesions arise from the same or clonally related progenitor cells [11]. The earlier 
study taken together with our results suggests that intraepithelial lesions of different grades 
on a multifocal cervix can arise simultaneously and therefore the “molecular switch” model 
(different methylation haplotype switches triggered at the same time) might be more likely than 
the “sequential progression” model (Figure 1). If CIN3 predominantly arose directly from 
adjacent-CIN1, we would expect to see methylation in the adjacent-CIN1 having a bridging 
pattern. Methylation of the adjacent-CIN1 should be very close to or at the same average level 
as the nearby CIN3 and such adjacent-CIN1 should be distinctly different than primary-CIN1; 
however, this was not what we observed. Although we cannot prove the actual overall secular 
Page 13 of 21 
mechanism of CIN3 origin from cross-sectional data, our results do suggest a model where 
CIN3 can emerge directly from normal epithelium, possibly simultaneously to CIN1. After that, 
lesions that persist can enlarge over time but retain their characteristic epigenotypes. This 
model is also consistent with what we see with respect to HPV type concordance in different 
lesions on the same cervix. An initial rapid progression to CIN3 may perhaps be driven by a 
series of epigenetic changes happening both before and during HPV infection. We propose 
that distinct epigenotypes underpin distinct morphologic patterns such as CIN1 or CIN3, 
explaining partially the different progression characteristics of these lesions. The drivers of 
epigenetic changes could be multiple. One possibility is that epigenetic changes, such as 
EPB41L3 methylation, may occur before hrHPV infection and facilitate the virus genome 
amplification and genetic instability phase, allowing in some women relatively rapid 
progression to CIN3. Furthermore, although most normal tissues have 0% methylation for 
EPB41L3, a sizeable proportion have modest elevation of EPB41L3 methylation of up to 10% 
[19, 24].   
 
As regards to HPV types, we found that most CIN1 and CIN3 lesions (69% in unifocal CIN1 
and 81% in multifocal CIN3 cases) were infected by a single hrHPV type. Our data partly 
confirm a similar study by Quint [32] where an association of a single HPV type with a discrete 
area of CIN was found for 93% (372/399) of laser capture micro-dissected tissue fragments 
they analysed by PCR. Van der Marel et al have suggested that multiple high-grade lesions 
on the cervix are often caused by a single carcinogenic genotype while other carcinogenic 
HPV types detected in cervical smears of the same patients are related to independent 
transient infections [39]. They support the “one virus-one lesion” hypothesis and discount 
biological interactions of multiple HPV infections on the lesion level [32]. 
 
We also showed that when multiple lesions of the same grade were present in a multifocal 
CIN3, they were very often infected by the same HPV type (81% in CIN3 and 91% in CIN1). 
However, in principal-CIN1 only 56% of the multiple CIN1 dissected were infected by the same 
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HPV type. This indicates that when lower-grade lesions are the primary diagnostic 
manifestation of HPV infection the distinct lesions are often infected by different and presumed 
transient HPV types.  
 
There were consecutively large differences and an overall significant Cuzick test trend of 
increased methylation with increasingly severe intraepithelial histopathology, going from 
normal to CIN1 to CIN3. These effects were seen for both EPB41L3 and HPVme-All, and were 
very similar to results we obtained earlier on exfoliated cervical specimens. The correlation 
between biopsies and scrapes allows a generalization of our findings to specimens obtained 
by cervical scraping and vaginal self-sampling [24, 38].  
 
Our study has some limitations. While the epigenetic switch model can underpin added 
insights for understanding epidemiologic and molecular distinctions between disease 
transitions in cervical pathogenesis a limitation is our inability to formally prove the methylation 
haplotype switch. However, the same caveat applies to the sequential model, conception of 
which developed over decades, predominantly on the basis of logical but unproven 
assumptions. A definitive study would require lengthy (possibly decades long) follow-up of 
large groups of women with HPV infection. The cervical lesions would require detailed 
topological mapping with frequent sampling of changing tissues areas by biopsies (which may 
affect the course of disease) and carefully directed scrapes, coupled to extensive molecular 
investigations. Such an in vivo mapping would no doubt quickly run into ethical concerns. We 
need to bear in mind that the two models are compatible and possibly both are correct in 
certain situations. Although our data support the idea that most CIN3 arise via a haplotype 
epigenetic switch some CIN3 may develop via a sequential progression.  
 
 A strength of our study is the use of an expertly rendered consensus CIN3 histopathological 
diagnosis as the primary endpoint rather than CIN2/3 or routine practice CIN3. Previous 
studies have shown that CIN2 is an equivocal diagnosis of precancer and more importantly in 
Page 15 of 21 
this context CIN2 has very poor inter-rater agreement [27, 29, 40, 41] and is much more likely 
to regress than CIN3 [42, 43]. Therefore, the grading of CIN2/3 may vary depending on the 
person rendering the diagnosis or on the follow-up protocol, making comparisons of risks 
between studies including CIN2 as an endpoint challenging to interpret. In addition, we used 
a highly accurate pyrosequencing method of DNA methylation measurement, shown to have 
high precision and low bias, which provided quantitative results expressed as a percentage 
from 0 to 100. We performed a molecular examination of multifocal intraepithelial lesions 
within the same patients, with direct quantitative contrasts to adjacent lesions and lesions from 
other women.  
 
While our data suggest at least two discrete epigenetic states (CIN1 and CIN3), we cannot 
say whether there are more epigenotypes. It is unlikely that our results were biased by the 
contamination of dissected lesions with other CIN or surrounding normal cells. All lesions were 
expertly marked by our team histopathologist (JC) and then dissected, carefully avoiding areas 
of other CIN and normal tissue. While the isolated CIN DNA probably had a low level of 
contamination from normal DNA the latter tissues were predominantly either not methylated 
or were methylated at lower levels than the CIN. Furthermore normal contamination on 
average would have been similar for principal-CIN1 and adjacent-CIN1, which were our most 
important comparison groups.  
 
There are many remaining questions and it is clear that relatively little is known about specific 
genetic and epigenetic mutations that underpin the evolution of CIN3, nor exactly which steps 
have a required sequence that then further facilitate the transformation of CIN3 to malignancy. 
A lot is known about molecular and mechanistic aspects of oncogenes, tumour suppressor 
genes, regulatory RNA pathways, multi-protein pathways etc. and also that many such 
pathways may become abnormal during carcinogenesis. However, for any given woman it is 
still not possible to predict accurately whether she will develop cervical cancer, what specific 
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constellation of pathway abnormalities would lead to the cancer and over what timeframe this 
will occur.  
 
In conclusion, we show for the first time that, although adjacent CIN of different grades usually 
contain the same hrHPV type(s), methylation patterns are significantly different and 
characteristic of the lesion grade, supporting a “molecular switch” model of progression to 
CIN3 that may be characterizable by distinct methylation haplotype patterns. Methylation 
testing may be an effective triage tool to detect and characterize women at high risk of 
developing CIN3 and cancer. Our results may influence the screening process in many ways, 
for example by providing an objective method to reach more accurate prognoses or by helping 
to avoid overtreatment of women with non-progressive lesions. Reducing the numbers of 
younger women treated by surgical excisions would have an important effect in preserving the 
ability of women to have uncomplicated pregnancies and to overall improve childbearing at a 
later date.  
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Figure 1 Current alternative cervical cancer progression models. In the sequential progression 
model (A), a long-lasting HPV infection causes cervical intraepithelial neoplasia (CIN) changes 
in consecutive steps from low grade CIN1 to high grade CIN3 and finally cancer. An alternative 
concept, the molecular switch model B), assumes that CIN1 is not necessary for the 
development of CIN3. CIN3 could evolve straight from normal epithelium infected by HPV. 
Here, we propose that distinct epigenotypes trigger distinct morphologic changes such as 
CIN1 or CIN3 independently, explaining partially the versatile nature of these lesions. Double-
sided arrows indicate possible regression.  
 
Figure 2. Flow chart showing the number of cases and dissected areas used for the main 
study including loop electrosurgical excision procedure (LEEP; tissues, centre main panel) 
and punch biopsies for the pilot study (top main panel). For some cases several CIN1 or CIN3 
areas were dissected per cervixA. Sections of five CIN1 and eight CIN3 cases had no normal 
epithelium B. Sections of ten CIN3 cases had no adjacent- CIN1 lesions C. Mean methylation 
levels were averaged per lesion typeD. HPV genotyping was done separately for all lesions. 
Our study also included a comparison of HPV typing data from the 127 LEEP to corresponding 
exfoliated cell specimens (right panel). Abbreviations; Adj.: adjacent, AVER: data averaged 
per lesion type, CIN: cervical intraepithelial neoplasia, IMP: data imputation, Prin.: principal, 
vs.: versus, 
 
Figure 3. A paired analysis comparison of methylation levels between adjacent cervical tissue 
samples from the same women. Methylation levels of sample pairs from unifocal principal-
CIN1 cases are shown on the left panel and sample pairs from multifocal CIN3 cases on the 
right panel for human gene EPB41L3 (A) and HPVme-All (B). Adjacent normal tissue samples 
were significantly different from their concurrent CIN1 in both unifocal and multifocal cases 
(EPB41L3 unifocal: p=0.0007, and multifocal: p=0.005; HPVme-All unifocal: p=0.0002 and 
multifocal cases: p=2e-04). In multifocal CIN3 cases, the CIN3 lesions were significantly 
different from the adjacent-CIN1 lesions (EPB41L3: p=0.008; HPVme-All: p=0.011). All 
pairwise comparisons were tested with Wilcoxon matched-pairs signed rank tests. 
Abbreviations; Adj.: adjacent, Prin.: principal. 
 
Figure 4. Differences in DNA methylation levels between adjacent lesions from the same 
cervix for EPB41L3 (A) and HPVme-All (B). The median differences were all positive and a 
large majority of individual differences were also positive, suggesting an increase of 
methylation with the severity of the lesion in cervical tissues of each woman. As expected the 
biggest difference was found between normal tissue samples and their adjacent CIN3 lesions 
in the multifocal CIN3 cases. Abbreviations; Adj.: adjacent, Prin.: principal 
 
Figure 5. DNA methylation levels of normal (white), CIN1 (light grey) and CIN3 (dark grey) 
samples, analysed in an unpaired manner. Methylation levels of CIN1 specimens were similar 
whether originating from principal-CIN1 cases (indicated by CIN1<CIN1) or from adjacent-
CIN1 near to CIN3 (CIN1<CIN3) for both A) EPB41L3 (p=0.497) and B) HPVme-All (p= 0.110). 
Methylation patterns were also similar for normal tissues taken from CIN1 cases 
(normal<CIN1) and CIN3 cases (normal<CIN3) for EPB41L3 (p=0.212) and HPVme-All 
(p=0.163). All comparisons tested with Mann-Whitney tests. 
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Figure 6. Percentage of samples infected by hrHPVs. In all sample types, single HPV 
infections were more frequent than multiple infections. Adjacent normal tissue samples 
presented a higher number of hrHPV negative samples (23% and 27% in unifocal principal- 
CIN1 and multifocal CIN3 cases respectively) compared to the intraepithelial lesions: principal-
CIN1 (4%), adjacent-CIN1 (3%) and CIN3 (1%). Most CIN1 lesions were infected by hrHPV 
types (87% of principal-CIN1 and 97% in adjacent-CIN1). All CIN3 samples, except one, were 
infected by hrHPV types. Abbreviations; Adj.: adjacent, Norm: normal, Prin.: principal. 
 
Supplementary Figures legends 
Supplementary figure 1. Methodology for sectioning, annotating and dissecting LEEP tissue 
blocks. Twelve 5um sections per block were cut. The first and last sections were used for 
haematoxylin and eosin staining (H&E) and sent for histopathological review and annotation. 
The annotated slides were used to dissect the CIN lesions and normal tissues of the remaining 
ten unstained sections. This material was used to purify DNA for subsequent analysis. 
Abbreviations; Adj: adjacent; Norm: normal; Prin: principal.  
 
Supplementary figure 2. DNA methylation levels of normal, CIN1 and CIN3 punch biopsies for 
human genes EPB41L3 (A) and MAL (B), HPV16 L1 region (C), L2 region (D), E2 binding site 
1 (E), E2 binding sites 3 and 4 (F) and HPV 18 L2 region (G). Significance level is shown with 
the horizontal bars above the boxplots; KWT 2: Kruskal-Wallis test statistic, CTT 2: Cuzick 
test for trend statistic, ns: non-significant, *: p<0.05, **: p<0.001, ***: p<0.0001.  
 
Supplementary figure 3. Comparison of HPV types found between adjacent tissue samples of 
different lesion grades. In the CIN3 cases, 87% of the adjacent-CIN1 lesions presented the 
same (or compatible) HPV type(s) as their nearby CIN3 lesions. A compatible type was 
defined as samples containing a matching HPV type in addition to other HPV types. Normal 
tissue samples showed fewer similarities when compared to adjacent-CIN1 (39%) or CIN3 
samples (33%) in the multifocal CIN3 cases. This number amounted to 45% in principal-CIN1. 
A substantial number of normal samples were HPV negative and no comparison could be 
made for these samples. Abbreviations; Adj: adjacent; Norm: normal; Prin: principal. 
 
What’s new? (Lay abstract) 
A better understanding of molecular mechanisms in skin tissue leading from human 
papillomavirus (HPV) infection to precancerous lesions is key to efficient prevention and 
treatment of HPV disease. Despite best efforts, accurate prediction of cancer progressive 
potential in HPV-infected patients remains inconsistent and elusive. We studied DNA 
methylation patterns to investigate models of HPV disease progression in areas of the uterine 
cervix with complex multi-focal precancerous cervical lesions. Carefully isolated disease foci 
of different grades were tested for molecular signatures. Methylation levels were much higher 
in women with high grade disease than low grade disease. Low grade lesions adjacent to high 
grade lesions predominantly shared the same HPV types whereas their DNA methylation 
patterns differed substantially; however, in women where only low grade disease was found 
on the cervix the methylation in these lesions was indistinguishable from low grade lesions 
adjacent to high grade lesions. We propose that progression from normal HPV-infected 
epithelium to low grade lesions or high grade lesions is generally promoted by the same 
persistent HPV type infections but occurs via distinct DNA methylation processes. Our data 
support a “molecular switch” model of precancer development which can lead to improved 
quantitation functions for cancer risk.    
 
 
 
 
 
